Research programme: ENPP1 inhibitors - Stingray Therapeutics
Latest Information Update: 24 Oct 2023
At a glance
- Originator Stingray Therapeutics
- Class Anti-infectives; Antibacterials; Antivirals; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections; Haemophilia; Hepatitis B; Lupus nephritis; Mycobacterium avium complex infections; Tuberculosis
Most Recent Events
- 05 Oct 2023 Early research in COVID-2019 infections in USA (unspecified route) before October 2023 (Stingray Therapeutics pipeline, October 2023)
- 05 Oct 2023 Early research in Haemophilia in USA (unspecified route) before October 2023 (Stingray Therapeutics pipeline, October 2023)
- 05 Oct 2023 Early research in Hepatitis B in USA (unspecified route) before October 2023 (Stingray Therapeutics pipeline, October 2023)